Search

Your search keyword '"Cannella, L"' showing total 3 results
Start Over Author "Cannella, L" Journal cancer chemotherapy and pharmacology
3 results on '"Cannella, L"'

2. Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?

Author

Breccia M, Frustaci AM, Cannella L, Soverini S, Stefanizzi C, Federico V, Grammatico S, Santopietro M, and Alimena G

Subjects
Benzamides, Drug Resistance, Neoplasm genetics, Female, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Middle Aged, Mutation drug effects, Piperazines pharmacology, Protein-Tyrosine Kinases antagonists & inhibitors, Pyrimidines pharmacology, Antineoplastic Agents pharmacology, Drug Resistance, Neoplasm drug effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Protein Kinase Inhibitors pharmacology
Abstract

With the increasing use of new tyrosine kinase inhibitors it has been suggested that the spectrum of kinase domain mutations may change and possible selection of new resistant clones may occur. We describe a Ph + chronic myeloid leukaemia (CML) patient with primary resistance to imatinib who received without success sequential therapy with multiple TKIs, and developed sequential emergence of kinase domain mutations after these treatments.

Published
2009
Full Text
View/download PDF

3. Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.

Author

Breccia M, Cilloni D, Cannella L, Stefanizzi C, Tafuri A, Fama A, Santopietro M, Saglio G, and Alimena G

Subjects
Adult, Benzamides, Dose-Response Relationship, Drug, Drug Administration Schedule, Eosinophils cytology, Eosinophils drug effects, Humans, Hypereosinophilic Syndrome genetics, Imatinib Mesylate, Leukocyte Count, Male, Patient Compliance, Piperazines therapeutic use, Pyrimidines therapeutic use, Recurrence, Remission Induction, Drug Dosage Calculations, Hypereosinophilic Syndrome drug therapy, Oncogene Proteins, Fusion genetics, Piperazines administration & dosage, Pyrimidines administration & dosage, Receptor, Platelet-Derived Growth Factor alpha genetics, mRNA Cleavage and Polyadenylation Factors genetics
Abstract

Imatinib is the treatment of choice for FIP1L1-PDGFRalpha (F/P+) positive myeloproliferative neoplasms, but little is known about optimal dose and duration of treatment to maintain complete molecular remission once achieved. We describe a case of F/P+ patients who started imatinib and reached a molecular remission, but did relapse after 15 months of therapy for poor adherence to therapy, and re-obtained remission only with standard dose of 400 mg/day. We reviewed the literature and highlights the need of quantitative molecular procedures to modulate imatinib dose.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results